Gene Therapy Consortium – Rett Syndrome Research Trust
Posted: December 14, 2017 at 12:43 pm
$3,595,265 AWARDED
Rett Syndrome, as awful as the symptoms may be, provides us with several enormous advantages. First we know the cause: mutations in a single gene: MECP2. Second, Rett is not degenerative brain cells dont die. Third, work from RSRT trustee, Adrian Bird, suggests that the symptoms of Rett need not be permanent. These three facts make gene therapy an attractive therapeutic strategy.
In 2014 we launched a bold international collaboration of two gene therapy labs, Brian Kaspar and Steven Gray, and two MECP2 labs, Gail Mandel and Stuart Cobb. Together these labs brought together all the necessary skills and experience to determine if gene therapy is a viable therapeutic.
The Consortium worked through numerous challenges involving vector optimization (the Trojan horse that delivers the gene into a cell), gene construct optimization (what you package into the vector that regulates MeCP2 protein production), gene therapy dosage, and the best route to deliver it.
The data generated by the Consortium exceeded our expectations. They were able to develop a gene therapy product candidate with impressive efficacy, safety and delivery characteristics. Importantly, the magnitude of improvement in the mouse models of Rett is much greater than that of any drug tested and suggests that significant benefit may be achieved in people. We expect improvements, at least to some degree, regardless of age.
Based on the Consortium data the biotech company, AveXis, has now committed to advancing a gene therapy candidate into clinical trials. The company will announce before the end of 2017 what their timeline for trials will be.
Technological advances in gene therapy are happening quickly with more effective vectors being discovered that can carry larger DNA cargos and target a greater percentage of brain cells. While we anticipate encouraging results with our first clinical trial there will undoubtedly be room to improve. We have therefore recently awarded continued funding to the Gene Therapy Consortium to support second-generation gene therapy programs to leverage all technological advances.
Targeting the root problem in Rett, MECP2, can be done either at the DNA level (gene therapy or MECP2 Reactivation), the mRNA level or protein level.
Both the DNA and protein approaches carry a risk of potential dosage problems (too much MeCP2 may be harmful). An alternative approach is to use a technology called Spliceosome-Mediated RNA Trans-Splicing (SMaRT). This technology allows a mutation to be spliced out and repaired in RNA. The advantage is that this approach avoids any potential over-expression issues. Consortium member, Stuart Cobb, is working on this approach.
Gail Mandel of the Consortium is working on yet another approach, RNA editing. The possibility of correcting mutations in RNA has profound therapeutic potential, but had remained largely theoretical. Our focused investments have already demonstrated the potential for correcting MECP2 mutations in RNA in cells. We are currently increasing our investment to improve the editing efficiency and to identify optimal delivery methods.
See original here:
Gene Therapy Consortium - Rett Syndrome Research Trust
- Journal of Stem Cell Research and Therapy- Open Access ... - February 13th, 2019
- Gene Therapy Initiative - gilbertfamilyfoundation.org - January 23rd, 2019
- AveXis Research & Development - November 14th, 2018
- Cell and Gene Therapy | Alliance for Cancer Gene Therapy ... - November 13th, 2018
- Gene Therapy Market Share Insights - Grand View Research - November 13th, 2018
- What is gene therapy? - Genetics Home Reference - NIH - October 14th, 2018
- Gene Therapy Manufacturing - The Bioprocessing Summit - September 29th, 2018
- The Gene Therapy Plan: Taking Control of Your Genetic ... - September 27th, 2018
- GeoGene: Gene Therapy, What it is, The process and Vectors ... - September 27th, 2018
- Antiviral Gene Therapy Research Unit - Wits University - August 26th, 2018
- Gene Therapy Research | Ophthotech - August 7th, 2018
- Gene Therapy - Genetics Generation - July 26th, 2018
- Gene Therapy Clinical Research - nationwidechildrens.org - July 9th, 2018
- The Cancer Gene Therapy Research Team | Kids Research - June 21st, 2018
- World Gene Therapy Research Report 2018: Technologies ... - May 30th, 2018
- Operationalizing Gene Therapy Trials - Premier Research - May 13th, 2018
- Gene therapy - Mayo Clinic - April 22nd, 2018
- Center for Gene Therapy :: The Research Institute at Nationwide ... - April 12th, 2018
- Human Gene Therapy | Mary Ann Liebert, Inc. publishers - March 23rd, 2018
- Foundation Fighting Blindness Celebrates Historic FDA ... - March 16th, 2018
- Gene Therapy Clinical Trials Databases - March 16th, 2018
- Gene therapy | medicine | Britannica.com - February 7th, 2018
- The coming of age of gene therapy: A review of the past ... - January 16th, 2018
- Gene therapy comes of age | Science - January 16th, 2018
- Gene therapy - About - Mayo Clinic - December 26th, 2017
- Germline Gene Transfer - National Human Genome Research ... - December 13th, 2017
- Small viruses could accelerate cell and gene therapy research - December 13th, 2017
- Gene therapy at OHSU Casey Eye Institute | Casey Eye ... - December 3rd, 2017
- Gene Therapy Advisory Committee - Health Research Authority - December 2nd, 2017
- Gene therapy | Cancer in general | Cancer Research UK - September 26th, 2017
- Home - Cell & Gene Therapy World 2018 - Meet the Future of ... - September 20th, 2017
- FDA Vows Modernization to Keep Up With Biotech Advances - Bloomberg - September 7th, 2017
- Closer Than Ever to a Cure: Annual FA Fundraiser Sept. 22 in Branford - Zip06.com - September 7th, 2017
- Families raise money for research into rare diseases - KARE - September 6th, 2017
- Global Updated Gene Therapy Technologies, Markets and Companies Report 2017-2026 - Research and Markets - Business Wire (press release) - September 6th, 2017
- Renova Therapeutics co-founder awarded highest research honor ... - PR Newswire (press release) - September 6th, 2017
- Upcoming Duchenne Gene Therapy Trial to Be Focus of PPMD-hosted Webinar on Wednesday, Sept. 6 - Muscular Dystrophy News - September 6th, 2017
- Has the Era of Gene Therapy Finally Arrived? - Scientific American (blog) - September 6th, 2017
- Opinion: How investors should play gene-therapy stocks - MarketWatch - September 6th, 2017
- Lasker Awards honor Planned Parenthood and research on preventing and fighting cancer - Los Angeles Times - September 6th, 2017
- Stevenage-based Cell and Gene Therapy Catapult gets 12 million ... - Comet 24 - September 1st, 2017
- News of NoteGene therapy to protect the heart; boosting chemo with cardio drugs; reversing memory loss - FierceBiotech - September 1st, 2017
- Gene therapy using 'junk DNA' could lower risk for heart disease - UCLA Newsroom - September 1st, 2017
- A 'historic' cancer treatment designed by Penn researchers just got approved by the FDA - The Daily Pennsylvanian - September 1st, 2017
- 'Hit-and-run' gene therapy nanoparticles could enhance CAR-T ... - FierceBiotech - September 1st, 2017
- Ipswich resident Talia Duff's fight for life continues, family hopes to raise funds for research - Wicked Local Ipswich - August 29th, 2017
- Global Cartilage Repair Market 2017-2021 - Gene Therapy and Stem Cell Therapy is the latest Market Trend Making ... - Business Wire (press release) - August 29th, 2017
- $91M Deal: CSL Acquires California Stem Cell Gene Therapy Developer - NBC 10 Philadelphia - August 29th, 2017
- RegenxBio to Acquire Dimension Tx in Combo of Gene Therapy Companies - Xconomy - August 25th, 2017
- Global Gene Therapy Partnering Terms and Agreements 2010 to ... - Business Wire (press release) - August 25th, 2017
- Cambridge gene therapy firm Dimension Therapeutics to be acquired - Boston Business Journal - August 25th, 2017
- Birth control research is moving beyond the pill - Science News Magazine - August 23rd, 2017
- Apic Bio Launches to Advance First-in-Class Gene Therapy for ... - Business Wire (press release) - August 23rd, 2017
- Comic and Telethon Host Jerry Lewis Dies At 91 - WebMD - August 22nd, 2017
- Pacific Biosciences Is Advancing Genomics - Seeking Alpha - August 22nd, 2017
- Scientists foresee Russian gene therapy for HIV cure may be registered in 5-10 years - TASS - August 20th, 2017
- Why three little virus-free pigs matter - The Messenger (subscription) - August 20th, 2017
- Listening for the Public Voice - Slate Magazine - August 17th, 2017
- Cancer Gene Therapy Market - Forecasts and Opportunity Assessment by Technavio - Business Wire (press release) - August 17th, 2017
- Gene Therapy | Pfizer: One of the world's premier ... - August 17th, 2017
- Pfizer commits $100M for a gene therapies plant in North Carolina - FiercePharma - August 15th, 2017
- Grant enables study of mosquito virus as a genetic lab tool, malaria biocontrol - Penn State News - August 15th, 2017
- Skewing the Aim of Targeted Cancer Therapies - Research Horizons - August 15th, 2017
- Gene Editing System Revamped to Target RNA Aggregates Found in Inherited ALS - ALS News Today - August 15th, 2017
- Pfizer Plans Gene Therapy Manufacturing Investment in North ... - BioPharm International - August 11th, 2017
- MoU signed to commercialise gene therapy in India - Odisha Sun Times - August 11th, 2017
- Americans want a say in human genome editing, survey shows - Los Angeles Times - August 11th, 2017
- Skin transplants could treat diabetes and obesity - Futurity: Research News - August 10th, 2017
- UCSD team adapts CRISPR to edit RNA for disease therapies - The San Diego Union-Tribune - August 10th, 2017
- Drugmakers' hopes for gene therapy rise despite tiny sales in Europe - Reuters - August 10th, 2017
- Pfizer chooses Sanford, North Carolina site for $100m gene therapy plant - BioPharma-Reporter.com - August 9th, 2017
- Pfizer investing $100M in Sanford plant expansion, adding jobs ... - Triangle Business Journal - August 9th, 2017
- Silverstein-backed startup will test gene therapy for Parkinson's - FierceBiotech - August 9th, 2017
- Pfizer to invest $100M in Sanford gene therapy operation, add jobs ... - WRAL Tech Wire - August 9th, 2017
- Pfizer Inc. Expands Biopharmaceutical Research Center in Sanford, North Carolina - Area Development Online - August 9th, 2017
- Gene Therapy Is Now Available, but Who Will Pay for It? - Scientific American - August 9th, 2017
- Agilis Biotherapeutics and Gene Therapy Research Institution Enter ... - Business Wire (press release) - August 8th, 2017
- Cardiovascular disease cure? One session of THIS could help treat condition - Express.co.uk - August 8th, 2017
- Human embryos 'edited' from potentially fatal gene mutation - Jordan Times - August 6th, 2017
- Agilis Biotherapeutics, Gene Therapy Research Institution Enter Strategic Partnership - Drug Discovery & Development - August 4th, 2017